SOMATULINE® DEPOT PROVIDES ONCE-MONTHLY DOSING VIA DEEP SUBCUTANEOUS INJECTION FROM A PREFILLED AND READY-TO-USE SYRINGE1,2
The formulation of Somatuline Depot enables steady release without the need for polymers or additives.2
High density of lanreotide nanotubes allows for low injection volume.2
Lanreotide is injected into the deep subcutaneous layer of the tissue. After injection, the formulation is thought to form a depot – or drug reservoir, for fast-acting (peak serum concentration of 7 hours) and sustained-release (half-life of 23 to 30 days) drug delivery.1,2
Lanreotide is slowly released, enabling delivery every 4 weeks.2
See the Pharmacokinetic profile of Somatuline Depot below
Discover more about the Somatuline Depot formulation and mechanism of action – watch now
Rapid onset of action and sustained-release formulation1,2
Somatuline Depot has been shown to reach peak serum concentration in 7 hours, followed by a steady and sustained release (half-life of 23 to 30 days)1,2
Serum concentrations achieved in healthy subjects following deep SC administration of Somatuline Depot2
- Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2023.
- Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366-374.